rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9.
|
29748615 |
2018 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence shows that exon 19 deletions (19del) and exon 21 Leu858Arg point mutation (L858R) of EGFR are different in response to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy in advanced lung cancers.
|
29026990 |
2018 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Next, we examined the role of RhoB in lung cancer progression in transgenic mice that express inducible EGFR(L858R) crossed with Rhob null mice.
|
25320360 |
2014 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The loop-hybrid mobility shift assay (LH-MSA) was previously developed for the rapid detection of the EGFR mutation L858R for predicting clinical responses to gefitinib in lung cancer.
|
21741959 |
2011 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aim to develop a digital PCR-based method for the quantitative detection of the two common epidermal growth factor receptor (EGFR) mutations (in-frame deletion at exon 19 and L858R at exon 21) in the plasma and tumor tissues of patients suffering from non-small cell lung cancers.
|
19276259 |
2009 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant.
|
23664448 |
2013 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic analysis suggested that the specific EGFR mutation L858R in exon 21 might be the main factor contributing to lung carcinogenesis in multiple lung cancers.
|
22733594 |
2012 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
|
31550632 |
2019 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
|
27433829 |
2016 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We identified a reference range for EGFR L858R and exon 19 deletions in specimens from KRAS-mutant lung cancer, allowing identification of candidate thresholds with high sensitivity and 100% specificity.
|
24429876 |
2014 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
To further access a physiological role of MALT1-dependent NF-κB activation in EGFR-driven tumor progression, we generated triple-transgenic mouse model (tetO-EGFR(L858R); CCSP-rtTA; Malt1(-/-)), in which mutant EGFR-driven lung cancer was developed in the absence of MALT1 expression.
|
25982276 |
2016 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resistance mutation.
|
23937717 |
2013 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ectopic expression of EGFR-L858R in lung cancer cells acted through activation of ERK signaling pathways to induce the expression of CXCR4.
|
26338423 |
2015 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Advanced lung cancers with epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19s) and EGFR exon 21 L858R point mutations (Ex21s) exhibit different clinical behavior.
|
26496308 |
2015 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Targeted therapy for these lung cancers has been established based on evidence regarding mainly common mutations; that is, exon 19 deletions (Del19) and L858R.
|
27323238 |
2016 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
|
27643705 |
2016 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The most frequent epidermal growth factor receptor (EGFR) mutations of lung cancer include exon 19 in deletion and the exon 21 L858R mutation.
|
29290255 |
2018 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We identified all patients with metastatic <i>EGFR</i> exon19del or L858R-mutant lung cancers treated with first/second-generation EGFR tyrosine kinase inhibitors (TKIs) with pretreatment next-generation sequencing data (MSK-IMPACT assay).
|
30045933 |
2019 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
|
20574956 |
2010 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we applied ORNi-PCR to simultaneous detection of the de novo L858R and acquired T790M mutations in the <i>EGFR</i> gene in lung cancer cells.
|
31426517 |
2019 |
rs1057519847
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |